Ophthalmic solution reduces IOP in phase 2 study
Click Here to Manage Email Alerts
Key takeaways:
- IOP decreased with the use of VVN539 in a phase 2 study.
- The ophthalmic solution was well tolerated and had positive safety results.
VVN539 ophthalmic solution met its primary endpoints for the treatment of primary open-angle glaucoma or ocular hypertension in a phase 2 study, according to a press release from VivaVision Biotech.
The double-masked, vehicle- and dose-controlled study investigated the ocular hypotensive efficacy and safety of VVN539 0.04% and 0.02%, a first-in-class dual mechanism of action small molecule, which showed a clinically and statistically significant decrease in elevated IOP.
VVN539 0.04% was statistically superior compared with vehicle at all nine time points over the 21-day study, with a decrease of 5 mm Hg to 6 mm Hg from unmedicated baseline. VVN539 0.02% demonstrated a statistically significant reduction in IOP from baseline at the majority of time points.
Results indicate VVN539 is safe and well tolerated in adult subjects.
Future clinical studies will compare VVN539 against a first-line hypotensive drug in a larger patient population, the release said.
Read more about
Click Here to Manage Email Alerts